Study of Ketamine Administered Intravenously and by Sublingual Wafer

NCT01377831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2015-03-10

No results posted yet for this study

Summary

To determine the rate and extent of of absorption of racemic ketamine from sublingual wafer

Conditions

Sponsors & Collaborators

  • iX Biopharma Ltd.

    lead OTHER

Principal Investigators

  • Pual Rolan · Pain and Anaesthesia Research Clinic - PARC

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01377831 on ClinicalTrials.gov